Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Chaman Lal Setia Exp Ltd Share Price

₹ 321.3 0.19 (0.05%)

Apr 16 2025 09:46 AM FMCG NSE: CLSEL

Chaman Lal Setia Exp Ltd Share Price Update

As of the latest trading session, Chaman Lal Setia Exp Ltd share price is currently at 321.3, which is up by 0.19 from its previous closing. Today, the stock has fluctuated between 320.00 and 325.25. Over the past year, Chaman Lal Setia Exp Ltd has achieved a return of 44.71 %. In the last month alone, the return has been 6.75 %. Read More...

Chaman Lal Setia Exp Ltd Performance

Day Range

Low320.00 High325.25

321.10

52 Week Range

Low 183.35 High 447.20

321.10

Chaman Lal Setia Exp Ltd Share Price

3482

530307

CLSEL

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

321.10 Prev. Close

321.10 Volume (Shares)

54307.00

Total traded value

174.37 Upper Circuit

385.30 Lower Circuit

256.90

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Chaman Lal Setia Exp Ltd Fundamentals

(Standalone)

Market Cap (Cr)	1661.20
PE Ratio (TTM)	16.11
Book Value / Share	115.20
Beta	0.96

ROE	19.89%
EPS (TTM)	19.63
Dividend Yield	0.71%
Net Profit Qtr (Cr)	29.01

Chaman Lal Setia Exp Ltd Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	395.30
Operating Expense	359.37
Net Profit	29.01
Net Profit Margin (%)	7.33
Earnings Per Share (EPS)	5.83
EBITDA	42.28
Effective Tax Rate (%)	25.06

Particulars	SEP 2024 (Values in Cr)
Revenue	369.43
Operating Expense	336.15
Net Profit	26.70
Net Profit Margin (%)	7.22
Earnings Per Share (EPS)	5.55
EBITDA	38.48
Effective Tax Rate (%)	25.21

Particulars	JUN 2024 (Values in Cr)
Revenue	362.84
Operating Expense	334.20
Net Profit	22.62
Net Profit Margin (%)	6.23
Earnings Per Share (EPS)	4.37
EBITDA	33.75
Effective Tax Rate (%)	25.22

Particulars	MAR 2024 (Values in Cr)
Revenue	383.53
Operating Expense	354.32
Net Profit	23.25
Net Profit Margin (%)	6.06
Earnings Per Share (EPS)	4.49
EBITDA	37.35
Effective Tax Rate (%)	24.90

Particulars	DEC 2023 (Values in Cr)
Revenue	400.07
Operating Expense	352.43
Net Profit	38.69
Net Profit Margin (%)	9.67
Earnings Per Share (EPS)	7.49
EBITDA	56.01
Effective Tax Rate (%)	25.07

Particulars	MAR 2024 (Values in Cr)
Revenue	1355.63
Operating Expense	1210.66
Net Profit	115.64
Net Profit Margin (%)	8.53
Earnings Per Share (EPS)	22.36
EBITDA	171.47
Effective Tax Rate (%)	25.16

Particulars	MAR 2023 (Values in Cr)
Revenue	1387.35
Operating Expense	1241.62
Net Profit	117.67
Net Profit Margin (%)	8.48
Earnings Per Share (EPS)	22.76
EBITDA	170.35
Effective Tax Rate (%)	25.14

Particulars	MAR 2022 (Values in Cr)
Revenue	932.49
Operating Expense	849.31
Net Profit	64.98
Net Profit Margin (%)	6.96
Earnings Per Share (EPS)	12.57
EBITDA	99.08
Effective Tax Rate (%)	25.35

Particulars	MAR 2021 (Values in Cr)
Revenue	851.49
Operating Expense	745.14
Net Profit	82.01
Net Profit Margin (%)	9.63
Earnings Per Share (EPS)	15.86
EBITDA	121.21
Effective Tax Rate (%)	25.21

Particulars	MAR 2020 (Values in Cr)
Revenue	797.69
Operating Expense	730.24
Net Profit	52.47
Net Profit Margin (%)	6.57
Earnings Per Share (EPS)	10.15
EBITDA	81.70
Effective Tax Rate (%)	25.17

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	122.58
ROE %	19.89
ROCE %	22.54
Total Debt to Total Equity	0.25
EBITDA Margin	12.65

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	102.19
ROE %	25.08
ROCE %	27.96
Total Debt to Total Equity	0.25
EBITDA Margin	12.28

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	79.17
ROE %	17.12
ROCE %	19.29
Total Debt to Total Equity	0.28
EBITDA Margin	10.63

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	67.58
ROE %	26.33
ROCE %	29.52
Total Debt to Total Equity	0.26
EBITDA Margin	14.24

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	52.82
ROE %	21.04
ROCE %	22.83
Total Debt to Total Equity	0.35
EBITDA Margin	10.24

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	67.25
Total Assets	994.40
Total Liabilities	994.40
Total Equity	713.96
Share Outstanding	51733500
Price to Book Ratio	1.66
Return on Assets (%)	11.62
Return on Capital (%)	13.01

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	45.42
Total Assets	817.97
Total Liabilities	817.97
Total Equity	608.45
Share Outstanding	51733550
Price to Book Ratio	1.68
Return on Assets (%)	14.38
Return on Capital (%)	16.14

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	6.43
Total Assets	620.98
Total Liabilities	620.98
Total Equity	409.55
Share Outstanding	51733550
Price to Book Ratio	1.24
Return on Assets (%)	10.46
Return on Capital (%)	12.32

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	63.21
Total Assets	519.15
Total Liabilities	519.15
Total Equity	349.60
Share Outstanding	51733550
Price to Book Ratio	1.27
Return on Assets (%)	15.79
Return on Capital (%)	18.41

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	15.44
Total Assets	423.87
Total Liabilities	423.87
Total Equity	273.26
Share Outstanding	51733550
Price to Book Ratio	0.65
Return on Assets (%)	12.37
Return on Capital (%)	15.38

Particulars	MAR 2024 (Values in Cr)
Net Income	154.52
Cash from Operations	11.72
Cash from Investing	-6.15
Cash from Financing	44.57
Net change in Cash	0.20
Free Cash Flow	25.42

Particulars	MAR 2023 (Values in Cr)
Net Income	157.20
Cash from Operations	46.42
Cash from Investing	-3.81
Cash from Financing	-4.39
Net change in Cash	-1.03
Free Cash Flow	55.48

Particulars	MAR 2022 (Values in Cr)
Net Income	87.04
Cash from Operations	-31.22
Cash from Investing	-7.10
Cash from Financing	15.14
Net change in Cash	-50.33
Free Cash Flow	-20.25

Particulars	MAR 2021 (Values in Cr)
Net Income	109.65
Cash from Operations	70.71
Cash from Investing	-7.80
Cash from Financing	21.72
Net change in Cash	51.30
Free Cash Flow	81.81

Particulars	MAR 2020 (Values in Cr)
Net Income	70.12
Cash from Operations	73.39
Cash from Investing	-18.55
Cash from Financing	-32.71
Net change in Cash	-0.32
Free Cash Flow	94.09

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
BRITANNIA INDUSTRIES LTD	5349.45	59.23	40.13	128851.29	4506.50 / 6473.10
NESTLE INDIA LIMITED	2360.85	72.40	2360.85	227623.04	2115.00 / 2777.00
FOODS & INNS LIMITED	82.32	24.95	1.17	604.35	75.20 / 177.45
HINDUSTAN UNILEVER LTD.	2366.60	53.71	10.95	556054.27	2136.00 / 3034.50
MILKFOOD LTD.	77.42	31.47	1.07	188.74	61.25 / 215.05

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
BRITANNIA INDUSTRIES LTD	5349.45	60.72	46.45	128851.29	4506.50 / 6473.10
COLGATE PALMOLIVE LTD.	2490.85	46.35	40.99	67747.54	2324.00 / 3893.00
NESTLE INDIA LIMITED	2360.85	72.55	57.04	227623.04	2115.00 / 2777.00
FOODS & INNS LIMITED	82.32	24.00	1.17	604.35	75.20 / 177.45

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 308.30
26 Days 306.70
10 Days 307.30
50 Days 311.90
12 Days 307.20
100 Days 316.00
20 Days 306.50
200 Days 301.10

317.22
PIVOT

First Resistance	325.48
Second Resistance	333.47
Third Resistance	341.73

First Support	309.23
Second Support	300.97
Third Support	292.98

RSI	56.30
MACD	0.49
Commodity Channel Index (CCI)	74.15

ADX	40.78
Williams % R	-23.22

Chaman Lal Setia Exp Ltd Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

21.52 Promoter Holdings

74.04 FII

1.86 DII

2.55 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Rajeev Setia	Shareholding of Promoter and Promoter Group	1.8209404E7	36.62
Vijay Kumar Setia	Shareholding of Promoter and Promoter Group	1.756724E7	35.33
Prudent Equity Ace Fund	Public Shareholding	702716.0	1.41
Altitude Investment Fund Pcc-cell 1	Public Shareholding	657077.0	1.32
Manohar Devabhaktuni	Public Shareholding	642108.0	1.29
Persistence Capital Fund 1	Public Shareholding	498578.0	1.0
Neelam Setia	Shareholding of Promoter and Promoter Group	295536.0	0.59
Sushma Setia	Shareholding of Promoter and Promoter Group	274924.0	0.55
Sankesh Setia	Shareholding of Promoter and Promoter Group	251096.0	0.5
Ankit Setia	Shareholding of Promoter and Promoter Group	162273.0	0.33
Sukarn Setia	Shareholding of Promoter and Promoter Group	41754.0	0.08
Manju Ahuja	Shareholding of Promoter and Promoter Group	8237.0	0.02
Lajwanti	Shareholding of Promoter and Promoter Group	2750.0	0.01
Kali Ram Suresh Kr	Shareholding of Promoter and Promoter Group	3850.0	0.01
Jagjit Singh	Shareholding of Promoter and Promoter Group	3850.0	0.01
Manoj Ahuja	Shareholding of Promoter and Promoter Group	0.0	0.0

Chaman Lal Setia Exp Ltd

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
21 Sep, 2023	1	Final	21 Sep, 2023	Equity shares
21 Sep, 2021	0.56	Final	23 Sep, 2021	Equity shares
21 Sep, 2020	0.5	Final	23 Sep, 2020	Equity shares
19 Sep, 2019	0.48	Final	21 Sep, 2019	Equity shares
19 Sep, 2018	0.42	Final	22 Sep, 2018	Equity shares
20 Sep, 2017	0.4	Final	22 Sep, 2017	Equity shares
21 Mar, 2016	0.44	Interim	22 Mar, 2016	Equity shares
19 Sep, 2014	1.5	Final	23 Sep, 2014	Equity shares
19 Sep, 2013	1.1	Final	23 Sep, 2013	Equity shares
20 Sep, 2012	1.6	Final	23 Sep, 2012	Equity shares
21 Sep, 2011	1.5	Final	23 Sep, 2011	Equity shares
21 Sep, 2010	1.6	Final	23 Sep, 2010	Equity shares
18 Sep, 2009	1.5	Final	23 Sep, 2009	Equity shares
19 Sep, 2008	1	Final	23 Sep, 2008	Equity shares
20 Sep, 2007	1.1	Final	23 Sep, 2007	Equity shares
21 Sep, 2006	0	Final	23 Sep, 2006	Equity shares
21 Sep, 2005	0	Final	23 Sep, 2005	Equity shares

Ex-Date	Ex-Bonus	Ratio
17 Oct, 2016	14 Oct, 2016	1:10

Ex-Date	Old FV	NEW FV	Record Date
28 Dec, 2015	10	2	29 Dec, 2015

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read